These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 23939631)

  • 1. Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women.
    Sherman ML; Borgstein NG; Mook L; Wilson D; Yang Y; Chen N; Kumar R; Kim K; Laadem A
    J Clin Pharmacol; 2013 Nov; 53(11):1121-30. PubMed ID: 23939631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testing for the erythropoiesis-stimulating agent Sotatercept/ACE-011 (ActRIIA-Fc) in serum by means of Western blotting and LC-HRMS.
    Walpurgis K; Thomas A; Vogel M; Reichel C; Geyer H; Schänzer W; Thevis M
    Drug Test Anal; 2016 Nov; 8(11-12):1152-1161. PubMed ID: 27649383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study.
    Cappellini MD; Porter J; Origa R; Forni GL; Voskaridou E; Galactéros F; Taher AT; Arlet JB; Ribeil JA; Garbowski M; Graziadei G; Brouzes C; Semeraro M; Laadem A; Miteva D; Zou J; Sung V; Zinger T; Attie KM; Hermine O
    Haematologica; 2019 Mar; 104(3):477-484. PubMed ID: 30337358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women.
    Ruckle J; Jacobs M; Kramer W; Pearsall AE; Kumar R; Underwood KW; Seehra J; Yang Y; Condon CH; Sherman ML
    J Bone Miner Res; 2009 Apr; 24(4):744-52. PubMed ID: 19049340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin.
    Carrancio S; Markovics J; Wong P; Leisten J; Castiglioni P; Groza MC; Raymon HK; Heise C; Daniel T; Chopra R; Sung V
    Br J Haematol; 2014 Jun; 165(6):870-82. PubMed ID: 24635723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activin receptor antagonists for cancer-related anemia and bone disease.
    Fields SZ; Parshad S; Anne M; Raftopoulos H; Alexander MJ; Sherman ML; Laadem A; Sung V; Terpos E
    Expert Opin Investig Drugs; 2013 Jan; 22(1):87-101. PubMed ID: 23127248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss.
    Raje N; Vallet S
    Curr Opin Mol Ther; 2010 Oct; 12(5):586-97. PubMed ID: 20886391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.
    Komrokji R; Garcia-Manero G; Ades L; Prebet T; Steensma DP; Jurcic JG; Sekeres MA; Berdeja J; Savona MR; Beyne-Rauzy O; Stamatoullas A; DeZern AE; Delaunay J; Borthakur G; Rifkin R; Boyd TE; Laadem A; Vo B; Zhang J; Puccio-Pick M; Attie KM; Fenaux P; List AF
    Lancet Haematol; 2018 Feb; 5(2):e63-e72. PubMed ID: 29331635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RAP-011, an activin receptor ligand trap, increases hemoglobin concentration in hepcidin transgenic mice.
    Langdon JM; Barkataki S; Berger AE; Cheadle C; Xue QL; Sung V; Roy CN
    Am J Hematol; 2015 Jan; 90(1):8-14. PubMed ID: 25236856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap.
    Iancu-Rubin C; Mosoyan G; Wang J; Kraus T; Sung V; Hoffman R
    Exp Hematol; 2013 Feb; 41(2):155-166.e17. PubMed ID: 23261964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From bench to bedside: The promise of sotatercept in hematologic disorders.
    Lan Z; Lv Z; Zuo W; Xiao Y
    Biomed Pharmacother; 2023 Sep; 165():115239. PubMed ID: 37516019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activin receptor ligand traps in chronic kidney disease.
    Jelkmann W
    Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):351-357. PubMed ID: 29847322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers.
    Attie KM; Allison MJ; McClure T; Boyd IE; Wilson DM; Pearsall AE; Sherman ML
    Am J Hematol; 2014 Jul; 89(7):766-70. PubMed ID: 24715706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies.
    Raftopoulos H; Laadem A; Hesketh PJ; Goldschmidt J; Gabrail N; Osborne C; Ali M; Sherman ML; Wang D; Glaspy JA; Puccio-Pick M; Zou J; Crawford J
    Support Care Cancer; 2016 Apr; 24(4):1517-25. PubMed ID: 26370220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RAP-011 improves erythropoiesis in zebrafish model of Diamond-Blackfan anemia through antagonizing lefty1.
    Ear J; Huang H; Wilson T; Tehrani Z; Lindgren A; Sung V; Laadem A; Daniel TO; Chopra R; Lin S
    Blood; 2015 Aug; 126(7):880-90. PubMed ID: 26109203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis.
    Suragani RN; Cadena SM; Cawley SM; Sako D; Mitchell D; Li R; Davies MV; Alexander MJ; Devine M; Loveday KS; Underwood KW; Grinberg AV; Quisel JD; Chopra R; Pearsall RS; Seehra J; Kumar R
    Nat Med; 2014 Apr; 20(4):408-14. PubMed ID: 24658078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sotatercept in patients with osteolytic lesions of multiple myeloma.
    Abdulkadyrov KM; Salogub GN; Khuazheva NK; Sherman ML; Laadem A; Barger R; Knight R; Srinivasan S; Terpos E
    Br J Haematol; 2014 Jun; 165(6):814-23. PubMed ID: 24650009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of activin receptor type IIA and IIB-Fc fusion proteins by automated capillary immunoassay.
    Desharnais P; Naud JF
    Drug Test Anal; 2022 Nov; 14(11-12):1938-1951. PubMed ID: 36200177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sotatercept Safety and Effects on Hemoglobin, Bone, and Vascular Calcification.
    Coyne DW; Singh HN; Smith WT; Giuseppi AC; Connarn JN; Sherman ML; Dellanna F; Malluche HH; Hruska KA
    Kidney Int Rep; 2019 Nov; 4(11):1585-1597. PubMed ID: 31891000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A validated, sensitive electrophoretic method for the detection of activin receptor type II-Fc fusion proteins in human blood.
    Martin L; Zouhiri N; Audran M; Marchand A
    Drug Test Anal; 2018 Mar; ():. PubMed ID: 29499588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.